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1. Preamble
1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for small for gestational age
(SGA) as an adverse event following maternal immunisation
Small for gestational age (SGA) fetuses or newborns are those
smaller in size than normal for their gestational age, most com-
monly defined as a weight below the 10th percentile for the gesta-
tional age. This classification was originally developed by a 1995
World Health Organization (WHO) expert committee, and the def-
inition is based on a birthweight-for-gestational-age measure com-
pared to a gender-specific reference population [1,2].
Successful pregnancy, including optimal growth of the fetus,
relies on a careful balance between immune tolerance and suppres-
sion. Several mechanisms work together to protect the fetus from
rejection [3]. During normal placentation, several changes occur,
including differentiation of the endometrium to decidua, develop-
ment of the fetal placental trophoplast to invade the decidua,
migration and differentiation of trophoblast, and remodeling of
the uterine arteries [4]. Current evidence suggests that the placenta
creates a micro-environment that controls immune cell differenti-
ation at the implantation site and trophoblastic cell-induced differ-
entiation of the immune cells into a phenotype beneficial for the
trophoblast [5]. Mor and Cardenas categorized pregnancy into three
different immunological stages [6]. The first pro-inflammatory
phase, occurring during the first trimester, includes implantation
and placentation. It is associated with increased levels of inter-
leukin (IL)-8, macrophage chemo-attractor protein 1 (MCP-1), and
activated T cells. The second anti-inflammatory phase, occurring
during mid-pregnancy, is a unique period of fetal growth and
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development. It is characterized by predominant anti-inflamma-
tory cytokines (IL-4, IL10 and IL-13). The third pro-inflammatory
phase is similar to the first phase, and it is a preparatory stage for
delivery [3]. Furthermore, different Pattern Recognition Receptors
(PRRs), including Toll-like receptors and Nod-like receptors, and
the innate immune system play a vital role in this process.
Dysfunction of the maternal innate immune response may pre-
dispose to placentally mediated diseases such as pre-eclampsia
(PET), fetal growth restriction (FGR), placental abruption, and
intrauterine fetal death. The complement system can affect angio-
genesis-related endothelial cell function. It can indirectly, through
macrophages, upregulate the anti-angiogenic soluble vascular
endothelial growth factor receptor-1 (SFlt-1). In addition, SFlt-1
can combine with soluble endoglin (sEnd) to induce PET, FGR,
and coagulation defects [7–10].
Traditionally, the causes for ‘‘pathological” growth restriction
are subdivided into fetal, placental and maternal. Genetic and
chromosomal disorders, fetal malformation, infection (e.g. rubella
or cytomegalovirus), and toxic substances (e.g. alcohol, cocaine,
or smoking) can contribute to FGR. Maternal diseases such as ane-
mia and malnutrition may also affect fetal growth. However, clas-
sical utero-placental dysfunction accounts for the vast majority of
cases of ‘‘placental” FGR, as well as to a variety of conditions such
as pre-eclampsia and placental abruption [11]. The Brighton Col-
laboration fetal growth restriction manuscript addresses the
impact of obstetric conditions on fetal growth restriction more
fully [12].
Congenital infections by Toxoplasma gondii, rubella, cytomega-
lovirus, herpes simplex virus (HSV), varicella-zoster virus, Tre-
ponema, and HIV contribute to 5–10% of fetal growth restriction
[13,14]. Several investigators believe that congenital infection
could be associated with a spectrum of disease, and it could be
quite variable, ranging from severe clinical manifestations to mild
disease only presenting with a small for gestational age fetus.
Many clinicians think that TORCH screens should be performed
on every SGA newborn infant [15–17].
Placental malaria is a major cause of fetal growth restriction. In
a case-control study of 492 pregnant Malawian women, a signifi-
cant increase of placental complement C5a levels was associated
with an increased risk of delivering a small-for-gestational-age
infant [18]. C5a was significantly increased in placental malaria
and was negatively correlated with the angiogenic factor angiopoi-
etin-1 and positively correlated with angiopoietin-2, soluble endo-
glin, and vascular endothelial growth factor [18].
Maternal vaccination during pregnancy has emerged as a rec-
ommended public health approach to prevent maternal and child-
hood infections. All current maternal vaccines were initially
designed for and tested in non-pregnant populations, but the
diverse immune modulations during pregnancy may cause preg-
nant women to respond sub-optimally or differently compared
with non-pregnant populations [19]. In addition, vaccine efficacy
could be affected by other factors including the dose, route, and
timing of the vaccination. Limited data exist on the effect of vacci-
nations in high-risk pregnancies. In spite of the success of several
maternal vaccines, many gaps exist in our knowledge of this
promising public health strategy and impact on fetal growth dur-
ing pregnancy.
Tetanus and influenza vaccines were the first vaccines recom-
mended for use during pregnancy. Trotta and colleagues evaluated
the safety of A/H1N1 pandemic vaccination of 6246 pregnant
women [20]. There was no difference in pregnancy outcome mea-
sures, including small for date. In an observational cohort study
from UK, Donegan and colleagues examined maternal and neonatal
outcomes among 6185 pertussis vaccinated pregnant women and
18,523 healthy unvaccinated historic controls [21]. There were
no significant differences between the two groups regarding low
birth weight or other maternal and neonatal outcomes [21], and
these findings were confirmed by others [22]. Currently, the World
Health Organization (WHO) provides guidance for vaccination dur-
ing pregnancy (Table 1). The key question that remains is related to
the safety and optimum timing of vaccination and if maternal vac-
cination has any negative effects on the immune system [23].
Placentally mediated severe FGR, indicated by abnormal uterine
and umbilical artery Doppler velocimetry, is associated with
impaired transplacental gas transfer and fetal hypoxaemia. This
triggers compensatory re-distribution of blood towards essential
organs (brain, heart, and adrenals) and decreases blood flow to
other organs (kidneys and bowel). This ‘‘compensatory phase” can
be recognised by observing Doppler changes (reduced resistance)
in the middle cerebral artery (MCA), decreased amniotic fluid,
and/or bright echogenic bowel. The duration of this compensatory
phase is variable. This phase is followed by a phase of myocardial
dysfunction and haemodynamic decompensation. This ‘‘decompen-
sation phase” can be recognised by abnormal venous Doppler
waveforms (absent or negative ‘a’ wave) and it is associated with
fetal acidaemia. Both hypoxaemia and acidaemia can also be
detected clinically by changes in fetal heart rate as well as the bio-
physical profile. The Brighton Collaboration growth restriction and
fetal distress guidelines further explore these issues [12,24].
Despite the presence of many pathophysiological events that
may lead to intrauterine growth restriction, SGA is not universally
associated with growth restriction. Small for gestational age (SGA),
is commonly used as a proxy for intrauterine growth restriction
(IUGR), particularly in settings where serial ultrasonography is
not readily available [2,25]. However, fetuses that are SGA are
not necessarily growth restricted; they in fact may be constitution-
ally small. If SGA babies have been the subject of intrauterine
growth retardation (IUGR), the term ‘‘SGA associated with IUGR”
is used. IUGR refers to a fetus that is unable to achieve its geneti-
cally determined potential size. This functional definition aims to
identify a population of fetuses at risk for poor pregnancy out-
comes, and excludes fetuses that are SGA but are not pathologically
small. Neonates born with severe SGA (or with severe short sta-
ture) are defined as having a length less than 2.5 standard devia-
tion below the mean [26].
A related term is low birth weight (LBW), defined as a birth
weight of less than 2500 g, regardless of gestational age at the time
of birth. Additional related terms include very low birth weight
(VLBW) which refers to less than 1500 g, and extremely low birth
weight (ELBW) which is less than 1000 g. Normal weight at term
delivery is 2500–4200 g. LBW is discussed further in a separate
document for this definition. It is important to be clear that SGA
is not a synonym of LBW, VLBW or ELBW. Approximately one third
of LBW babies weighing less than 2500 g are also SGA [12,27].
In this case definition and associated guideline, we propose a
systemic tool for evaluating the adverse event of SGA after mater-
nal immunisation. It is important to emphasize that these tools
have been developed in the absence of any data supporting such
an association but rather to facilitate studies of the safety of vacci-
nes used in pregnancy. The outcome of SGA has been examined in
several published studies of the safety of influenza and pertussis
vaccination during pregnancy. In one randomised clinical trial of
influenza immunisation in pregnant women in Bangladesh, SGA
was defined as less than 10th percentile weight for gestational
age [28,29]. In this trial, two reference standards were used - the
reference values for distributions of birth weights from the United
States [30] and the global reference standard from the World
Health Organization [31].
The remaining published studies were observational in design
and used different SGA definitions and reference standards
(Table 2) [32,33]. In most of these studies, SGA was defined as
the lowest 10th percentile of the gestational age-specific birth
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weight within the cohort of live births, not stratified or stratified by
gender [20,22,34–48]. In two studies, in addition to the 10th per-
centile cut-off, the investigators used other cut-offs to define very
small neonates, like low 3rd and low 5th percentiles [49,50]. In
three studies, SGA was defined as a births weight below 2 standard
deviations from the national reference mean [51–53].
Among the national population-basedweight references used by
the investigators, two older US population based standards were
mentioned [54,55], as well as population references for Taiwan
[56], France [57], Canada [58], The Netherlands [59], and Sweden
[53]. No published studies, however, provided details of how the
birthweight wasmeasured (e.g. the type of scales used) or specified
the age (in days) at which the measurements were taken.
The WHO definition of SGA, outlined by a 1995 WHO expert
committee, remains the most widely utilized definition of SGA
[1,2]. This classifies SGA infants as having a birth weight for gesta-
tional age below the 10th percentile based on a sex-specific refer-
ence population. Some infants classified as SGA will include
newborns who are constitutionally small and are in the lower tail
of the growth curve distribution, while others will include new-
borns who are growth restricted in utero due to one or more
growth-inhibiting factors such as malnutrition, placental insuffi-
ciency, pregnancy complications as preeclampsia, and/or infection
[2,60]. Other less utilized SGA definitions in the literature include
having a birth weight 2 standard deviations below the standard
for gestational age or a birth weight for gestational age below
the 5th or 3rd centile [60,61]. Using a more restrictive than a lib-
eral definition captures more severe cases of SGA rather than
infants who are constitutionally small.
Essential to the SGA definition is accurate dating of gestational
age [62,63] and accurate assessment of birth weight [27,61]. Early
ultrasound (accuracy ±5 days if first trimester and ±7 days after
first trimester), ideally in the first trimester, is the gold standard
for gestational age assessment [62,64]. Gestational age assessment
based on last menstrual period (LMP) date has lower accuracy
(±14 days) given different cycle duration in women, ovula-
tion/conception timing, and recall error [65]. The accuracy of new-
born physical examination (±13 days for Dubowitz) is influenced
by the complexity of the score used and the examiner’s expertise
level [64].
Table 1
Summary of vaccines reviewed and level of evidence concerning vaccine safety.
Vaccine Increased risk or severity of disease
in pregnant women
Risk of disease to fetus or young infant WHO recommendation
on vaccination during
pregnancy
Vaccine
safety
concerns
Level of
evidence on
vaccine safety
Inactivated vaccines
Seasonal TIV or H1N1
2009–2010
monovalent,
nonadjuvanted
vaccines
More severe disease especially in
second and third trimester and
increased risk of death in a
pandemic
Possible increased spontaneous
abortion rate and increased preterm
delivery. No malformations confirmed
Yes No SGA
safety
concerns
identified
++++
Oil-in-water adjuvanted,
monovalent H1N1
vaccines
Yes No SGA
safety
concerns
identified
+++
Tetanus toxoid vaccines Incidence depends on region;
unaltered by pregnancy
Neonatal tetanus mortality 60% Yes No SGA
safety
concerns
identified
++
Meningococcal
polysaccharide
vaccines
Incidence not altered by pregnancy Unknown for fetus; infants may
develop significant morbidity and
mortality.
No No SGA
safety
concerns
identified
++
Meningococcal
conjugate vaccines
As part of mass
campaigns.
No SGA
safety
concerns
identified
+
Live attenuated vaccines
Rubella vaccine Incidence not altered by pregnancy Abortion and congenital rubella
syndrome (CRS)
No No SGA
safety
concerns
identified
+++
Measles vaccines More severe disease; low mortality Possible higher abortion rate,
infrequently congenital measles and if
premature possible high case fatality
rate
No No SGA
safety
concerns
identified
Indirect data
from
combined MR
vaccines
Mumps vaccine Incidence not altered by pregnancy Probable increased rate of abortion in
the first trimester
No No SGA
safety
concerns
identified
Indirect data
from
combined MR
vaccines
Oral poliovirus vaccine Increased risk of paralytic disease Anoxic fetal damage reported; 50%
mortality in neonatal disease
No No SGA
safety
concerns
identified
+++
Yellow fever Incidence not altered by pregnancy Unknown During epidemics and
when travel to endemic
areas cannot be avoided
No SGA
safety
concerns
identified
+++
+++ Evidence from observational studies or registries with pregnancy follow-up and passive surveillance.
++ Some evidence from studies with lower power, lack of information on some relevant pregnancy outcomes, short follow-up of offspring or other limitations of study design
and passive surveillance.
+ Passive surveillance data.
– No data.
6520 E.P. Schlaudecker et al. / Vaccine 35 (2017) 6518–6528
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 22, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A main challenge in defining SGA is selecting the appropriate
comparison population [2,60,66]. It is important to select the
appropriate comparison charts as the rates of SGA can differ signif-
icantly based on the choice of the reference population [66,67].
There are two types of charts available including reference and
standard charts. Standard charts are prescriptive and delineate
how a population should grow under optimal environmental and
health conditions and are based on low-risk pregnancies [68,69].
Reference charts are descriptive, include both low-risk and high-
risk pregnancies, and specify growth in a particular place and time
[68,69]. A recent standard sex-specific birth weight for gestational
age chart using neonatal growth measures from healthy women in
eight countries with ultrasound assessed gestational age has been
published by the INTERGROWTH-21st Project group [70]. This
standard, based on a low-medium risk group of pregnant women,
is for infants born at 33–42 weeks’ gestation as too few women
gave birth to infants prior to 33 weeks [71]. The majority of the
charts in the literature are reference charts that differ considerably
in terms of sample size, population characteristics, representative-
ness (hospital based versus population-based), inclusion/exclusion
Table 2
Selected publications discussing maternal and fetal outcomes of vaccination during pregnancy and mentioning the outcome of Small for Gestational Age (SGA), among articles
published between 1 January 2006 and 1 June 2016. PubMed search strategy: (pregnancy OR pregnant) AND (vaccine OR vaccination OR immunisation) AND (pertussis OR Tdap
OR tetanus OR influenza); N = 1402 articles retrieved; 26 relevant publications extracted (by Vitali Pool, MD).
Reference SGA definition Vaccine #
Schatz et al. (2011) SGA defined as birth weight for gestational age <10th percentile Any [48]
Adedinsewo et al.
(2013)
SGA defined as the lowest 10th percentile of birth weight for each gestational week stratified by infant sex (reference values
from US dataa
IIV [34]
Ahrens et al. (2014) <10th percentile in weight for sex-specific gestational age IIV [35]
Baum et al. (2015) SGA; birth weight and/or length more than 2 SD below the sex- and gestational age-specific reference meanb IIV [51]
Beau et al. (2014) SGA was defined as any singleton with a birth weight <2 standard deviations (SD) from the French reference weight mean,
adjusted for gestational age and sexc
IIV [52]
Cantu et al. (2013) Defined by Brenner’s standard for fetal growth <10th percentiled IIV [36]
Chambers et al.
(2013)
<10th centile for sex and gestational age in live born infants using standard U.S. growth charts for full and preterm infantse IIV [37]
Dodds et al. (2012) 610th percentile IIV [38]
Fell et al. (2012) Two definitions were used to report fetal outcomes: (1) Small for gestational age: below 10th percentile, and (2) Small for
gestational age: below 3rd percentile
IIV [49]
Huang et al. (2014) SGA defined as live birth with birth weight <10th percentile for their gestational age (using Taiwan reference values for fetal
birth weights)f
IIV [39]
Källén et al. (2012) SGA defined as <2 SD from expected weight at the relevant gestational week. IIV [53]
Legge et al. (2014) SGA defined as the bottom 10th percentile of birth weight [for each sex] for each week of gestational age IIV [41]
Ludvigsson et al.
(2013)
SGA defined as <10th percentile of the gestational age-specific birth weight within the cohort IIV [42]
Nordin et al. (2014) Authors defined 2 cutoffs for SGA birth, <10th and <5th percentiles. Reference values for distributions of birth weights were
derived from US data, stratified by sexa
IIV [50]
Olsen et al. (2016) Gestational age was calculated by last menstrual period captured at the time of the first antenatal care visit. SGA was calculated
using the Kramer method, defined as a live birth with a birth weight <the 10th percentile of birth weights of the same sex and
same gestational age in weeksg
IIV [32]
Omer et al. (2011) Below the 10th percentile IIV [43]
Pasternak et al.
(2012)
Lowest 10th percentile of the gestational age-specific birth weight within the cohort IIV [44]
Richards et al.
(2013)
SGA not defined, but likely was <10th percentile weight for gestational age as used by the same authors in other studies/
publications
IIV [45]
Trotta et al. (2014) Live newborns with birth weight below the 10th centile for their gestational age within the cohort of live births only IIV [20]
van der Maas et al.
(2016)
SGA defined as a birth weight below the tenth centile, adjusted for gestational age and based on Dutch averagesi IIV [47]
Steinhoff et al.
(2012)
<10th percentile weight for gestational age; two reference standards were used – the reference values for distributions of birth
weights from USa and the Global reference standard by WHOh
IIV vs
PPSV
[28]
Steinhoff et al.
(2012)
<10th percentile weight for gestational age IIV vs
PPSV
[29]
Berenson et al.
(2016)
Below the 10th percentile Tdap [22]
Kharbanda et al.
(2014)
<10th percentile weight for gestational age Tdap [40]
Morgan et al.
(2015)
SGA outcome is reported but not clearly defined Tdap [33]
Sukumaran et al.
(2015)
Less than the 10th percentile for gestational age and sex Tdap [46]
NOTE: IIV – Inactivated Influenza Vaccine; Tdap – diphtheria, tetanus and acellular pertussis vaccine; PPSV – Pneumococcal Polysaccharide Vaccine.
a Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr.
2003 Jul 8;3:6. Epub 2003 Jul 8. (http://www.biomedcentral.com/1471-2431/3/6http://www.biomedcentral.com/1471-2431/3/6 accessed 31 May 2016)
b Sankilampi U, Hannila ML, Saari A, Gissler M, Dunkel L. New population-based references for birth weight, length, and head circumference in singletons and twins from 23
to 43 gestation weeks. Ann Med 2013;45(5–6 (Sep)):446–54.
c Salomon L-J, Bernard J-P, de Stavola B, Kenward M, Ville Y. Poids et taille denaissance: courbes et équations. J Gynecol Obstet Biol Reprod 2007;36(1):50–6.
d Brenner WE, Edelman DA, Hendricks CH. A standard of fetal growth for the United States of America. Am J Obstet Gynecol 1976;126:555–64.
e Lubchenco LO, Hansmann CO, Dressler M, Boyd E. Intrauterine growth as esti-mated from liveborn birthweight data at 24 to 42 weeks of gestaton. Pediatric-
s1963;32:793–800. Also in Lubchenco LO, Hansmann C, Boyd E. Intrauterine growth in length and headcircumference as estimated from libirth at gestational ages from 26 to
42 weeks. Pediatrics 1966;37:403–7.
f Hsieh WH, Wu HC, Jeng SF, et al. Nationwide singleton birth weight per-centiles by gestational age in Taiwan, 1998–2002. Acta Pediatr Taiwanica2006;47:25–33.
g Kramer MS, Platt RW,Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Bréart G; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A
new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001 Aug;108(2):E35.
h WHO Multicentre Growth Reference Study Group. WHO child growth standards: methods and development. Geneva (Switzerland): World Health Organization; 2006.
(www.who.int/childgrowth/standards/technical_report/en/www.who.int/childgrowth/standards/technical_report/en/ accessed 2011 Nov. 15).
i Visser GH, Eilers PH, Elferink-Stinkens PM, Merkus HM, Wit JM. New Dutch reference curves for birthweight by gestational age. Early Hum Dev. 2009 Dec;85(12):737–44.
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criteria, and methods of gestational age assessment [2,66]. A recent
meta-analysis identified 26 commonly cited reference charts
which include the 10th percentile cut point to define SGA status
[66]. The majority of the available reference populations were from
North America (n = 12) with some from Europe (n = 6) and Asia
(n = 5), and few from Africa (n = 2) and South America (n = 1)
[66]. The majority of the charts used LMP dates to define gesta-
tional age reported to the nearest week, while some used ultra-
sound or best obstetric estimate [66].
Customizing fetal size for maternal height, weight and
ethnicity, has been shown to improve the identification of babies
who are small because of FGR, rather than constitutional reasons
[72–77]. However, although maternal height, weight and ethnicity
are significant predictors of fetal size, they do not explain a large
proportion of the birth weight variability [78,79], and therefore,
their utility for customization is limited. Furthermore, it is impor-
tant to point out a major criticism to the customized fetal growth
charts. Arguably, their reported improved ability to identify fetuses
at risk of adverse outcome appears to be a consequence of an
artifact rather than a real improvement in predictive ability
[78,80–84]. The use of Hadlock’s proportionality formula to con-
struct these customized charts results in a substantially higher
proportion of preterm infants being identified as SGA. When this
artifactual identification of preterm infants is taken into account,
the reported benefits of customization disappear. It is likely though
that the use of customized charts is associated with improved
identification of SGA fetuses of mothers who smoke, have a high
body mass index or other pathologies [85].
Additionally important for preterm infants, the birth weight for
gestational age reference charts differ from ultrasound-based fetal
weight charts. Preterm infants are known to be smaller than in
utero infants given the underlying pathological determinants, such
as preeclampsia and other hypertensive disorders that impair fetal
growth and increase the risk of preterm birth [86–88]. As such, the
birth weight for gestational charts underestimate the prevalence of
IUGR [89].
Although there is a broadly accepted definition of SGA, the
aforementioned complexities involved in its evaluation, including
the accurate measurement of birth weight, the determination of
gestational age, and the reference chart used to analyze these data,
indicate that a standardized definition of SGA is desirable. This
need is especially apparent in studies of maternal immunisation
where SGA may be a critical endpoint, either as a positive outcome
related to vaccination or as related to safety. A positive effect of
immunisation in pregnancy might be that the infant is less likely
to be SGA. On the other hand, if the study vaccine somehow
adversely affects maternal health or other factors that impact birth
weight, then the increased incidence of SGA may indicate a safety
signal. A standard definition and evaluation of SGA would support
the comparability of conclusions related to the benefits and safety
concerns attributed to maternal immunisation with a given vac-
cine across studies. Herein, to facilitate data interpretation and
promote scientific understanding of the same, we propose the tools
necessary for determination of SGA in the setting of clinical trials
as well as post-licensure surveillance systems.
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for SGA as an adverse
event following maternal immunisation
Following the process described in the overview paper [90], as
well as on the Brighton Collaboration Website, http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Small for Gestational Age Working Group
was formed in 2016 and included members of clinical, academic,
public health, and industry backgrounds. The composition of the
working and reference group as well as results of the web-based
survey completed by the reference group with subsequent discus-
sions in the working group can be viewed at: http://www.brighton-
collaboration.org/internet/en/index/working_groups.html.
To guide the decision-making for the case definition and guideli-
nes, a literature search in PubMed was performed and identified
over twenty vaccine studies in which SGA was mentioned and
defined. (The search strategy used was as follows: (pregnancy OR
pregnant) AND (vaccine OR vaccination OR immunisation) AND
(pertussis OR Tdap OR tetanus OR influenza); article publication
dates between 1 January 2006 and 1 June 2016.) All abstracts were
screened for possible reports of small for gestational age following
immunisation. This review resulted in a summary of 26 articles,
including information on the diagnostic criteria or case definition
put forth and the vaccine used (summarized in Table 2). Multiple
general medical, paediatric and infectious disease text books were
also searched.Most publicationsdefinedSGAas the lowest 10thper-
centile of the gestational age-specific birthweightwithin the cohort
of live births, not stratified or stratified by gender [20,22,34–47].
1.3. Rationale for selected decisions about the case definition of SGA as
an adverse event following maternal immunisation
1.3.1. The term small for gestational age
Small for gestational age (SGA) is commonly used as a surrogate
marker of low fetal growth trajectories, and is indeed associated
with increased perinatal mortality and morbidity. In order to
define perinatal outcomes and identify safety issues during mater-
nal immunisation trials, this Brighton Collaboration case definition
of small for gestational age focuses on recommendations to simul-
taneously define both birthweight and gestational age. Within the
definition context, however, the three diagnostic levels must not
be misunderstood as reflecting different grades of clinical severity.
They instead reflect diagnostic certainty (see below).
1.3.2. Related terms - small for gestational age
The working group considered several other related outcomes
in its discussions. Principle consideration was given to both the
assessment of gestational age and assessment of size/weight as
both these formed the foundation for our definition. Accordingly,
we worked closely with the GAIA workgroups assigned to assess-
ment of prematurity [62,63] and also for low birth weight [27].
Our definition and Brighton level classification scheme draw upon
their work.
In addition, SGA, which assesses the size of the infant in relation
to its maturity after birth, is closely related to inter-uterine growth
retardationwhich assesses the growth of the fetus up until the time
of birth and when present predicts for an SGA infant. These two
entities, while closely related, use very different assessment tools,
so our definition presented here acknowledges the work of the
GAIA IUGR group [12] but did not draw upon their methods.
1.3.3. Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
It needs to be re-emphasised that the grading of definition
levels is entirely about diagnostic certainty, not clinical severity
of an event. Thus, a clinically very severe event may appropriately
be classified as Level Two or Three rather than Level One if it could
reasonably be of non-small for gestational age aetiology. Detailed
information about the severity of the event should additionally
always be recorded, as specified by the data collection guidelines.
The number of symptoms and/or signs that will be documented
for each case may vary considerably. The case definition has been
formulated such that the Level 1 definition is highly specific for
the condition. As maximum specificity normally implies a loss of
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sensitivity, two additional diagnostic levels have been included in
the definition, offering a stepwise increase of sensitivity from Level
One down to Level Three, while retaining an acceptable level of
specificity at all levels. In this way it is hoped that all possible cases
of SGA can be captured.
1.3.4. Rationale for individual criteria or decision made related to the
case definition
Our approach is to provide adequate diagnostic specificity with-
out being overly restrictive with the objective of making available
a definition that is applicable in high, middle, and low-income coun-
tries. Laboratory and pathology findings are not included in the case
definition as these examinations are not required to meet the case
definition of SGA. Assessment through imaging (ultrasound) at dif-
ferent gestational ages in pregnancy has been included to meet case
definition for levels of certainty 1A to 3A, as ultrasound represents
the most accurate method for assessment of gestational age.
1.3.5. Influence of treatment on fulfilment of case definition
The Working Group decided against using ‘‘treatment” or
‘‘treatment response” towards fulfillment of the SGA case defini-
tion, as specific SGA treatments are not currently used or accepted.
1.3.6. Timing post maternal immunisation
The diagnosis of SGA is made at birth after the measurement of
birth weight, calculation of gestational age and ascertainment of
weight for gestational age percentile when compared to a refer-
ence standard. Once the diagnosis has been made, no further
change would be anticipated. It is expected that the birth weight
and gestational age would have been obtained by a method consis-
tent with the Brighton Collaboration standards.
The timing of the vaccine receipt or the interval from maternal
immunisation and the neonatal birth are not elements of the SGA
definition. In fact, the definition is meant to stand alone indepen-
dent of whether the mother was vaccinated. A definition designed
to be a suitable tool for describing relationships requires ascertain-
ment of the outcome (e.g. SGA) independent from the exposure
(e.g. vaccination). Therefore, to avoid selection bias, a restrictive
time interval from vaccination to birth should not be an integral
part of such a definition. Instead, where feasible, information on
the timing of vaccine administration during pregnancy should be
collected, assessed and reported as described in the data collection
guidelines and the ascertainment of whether or not the infant is
SGA and the associated Brighton level should be determined by
personnel blinded to the vaccine status of the mother.
Further, SGA often occurs outside the controlled setting of a
clinical trial or hospital. In some settings it may be impossible to
obtain a clear timeline of the event, particularly in less developed
or rural settings. In order to avoid selecting against such cases,
the Brighton Collaboration case definition avoids setting arbitrary
time frames.
1.3.7. Differentiation from other (similar/associated) disorders
As described above, other similar disorders to SGA include
IUGR. While IUGR refers to reduced growth velocity in the fetus
as supported by at least two intrauterine growth assessments,
SGA does not reflect fetal growth but size of the infant at birth
[60,61,91]. Additionally, IUGR implies the presence of a pathologi-
cal condition that occurs in utero and results in diminished fetal
growth. An infant who is SGA however, does not imply that the
infant has suffered from IUGR, and infants who experience a short
duration of IUGR will not necessarily be SGA at birth [60,61,91].
1.4. Guidelines for data collection, analysis and presentation
Asmentioned in the overview paper, the case definition is accom-
panied by guidelines which are structured according to the steps of
conducting a clinical trial, i.e. data collection, analysis and presenta-
tion. Neither case definition nor guidelines are intended to guide or
establish criteria for management of ill infants, children, or adults.
Both were developed to improve data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of small for gestational age3
SGA (small for gestational age) definition: weight below 10th
percentile for gestational age as assessed against a validated global,
regional or local standard.
2.1. Brighton Level 1 of diagnostic certainty
 Weight below 10th percentile for gestational age
AND
 The following used in assessment of weight:
o Newborn weighed within 24 h of birth
o Weight assessed using a calibrated electronic scale with
10 g resolution
AND
 The following for assessment of gestational age:
o Certain LMP or IUI or embryo transfer date AND confirma-
tory ultrasound in first trimester
OR
 The following for assessment of gestational age:
o First trimester ultrasound
2.2. Brighton Level 2A of diagnostic certainty
 Weight below 10th percentile for gestational age
AND
 The following used in assessment of weight
o Newborn weighed within 24 h of birth on any scale with a
<50 g resolution, tared to zero and calibrated
AND
 The following for assessment of gestational age:
o Certain LMP with first or second trimester ultrasound
OR
o Certain LMP with first trimester physical exam4
2.3. Brighton Level 2B of diagnostic certainty
 Weight below 10th percentile for gestational age
AND
 The following used in assessment of weight
o Newborn weighed within 24 h of birth on any scale with a
<50 g resolution, tared to zero and calibrated
AND
 The following assessment of gestational age
o Uncertain LMP with second trimester ultrasound
3 The case definition should be applied when there is no clear alternative diagnosis
for the reported event to account for the combination of symptoms.
4 If Physical exam and ultrasound do not correlate, default to ultrasound.
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2.4. Brighton Level 3A of diagnostic certainty
 Weight below 10th percentile for gestational age
AND
 The following used in assessment of weight
o Infant weighed within the first 48 h of life
o Newborn weighed on any scale with a <50 g resolution,
tared to zero and calibrated
AND
 The following assessment of gestational age
o Certain LMP with third trimester ultrasound
OR
o Certain LMP with confirmatory 2nd trimester fundal
height
OR
o Certain LMP with birthweight
OR
o Uncertain LMP with first trimester physical exam
2.5. Brighton Level 3B of diagnostic certainty
 Weight below 10th percentile for gestational age
AND
 The following used in assessment of weight
o Infant weighed within the first 48 h of life
o Newborn weight assessed by measuring the difference
between an adult holding the infant and the adult being
weighed alone on any scale
AND
 The following assessment of gestational age
o Uncertain LMP with fundal height
OR
o Uncertain LMP with newborn physical assessment
OR
o Uncertain LMP with birthweight
2.6. Brighton Level 4 of diagnostic certainty
– Baby noted to be small, but no actual weight
– Baby with GA assessed only by infant examination
– Diagnosis extracted from billing codes or chart, with no docu-
mentation of actual birth weight or GA
2.7. Brighton Level 5 of diagnostic certainty
– No evidence of SGA or a confirmed diagnosis other than SGA.
3. Guidelines for data collection, analysis and presentation of
small for gestational age
It was the consensus of the Brighton Collaboration Small for Ges-
tational Age Working Group for small for gestational age (SGA) to
recommend the following guidelines to enable meaningful and
standardized collection, analysis, and presentation of information
about SGA. However, implementation of all guidelines might not
be possible in all settings. The availability of information may vary
depending upon resources, geographical region, and whether the
source of information is a prospective clinical trial, a post-market-
ing surveillance or epidemiological study, or an individual report of
SGA. Also, as explained in more detail in the overview paper in this
volume, these guidelines have been developed by this working
group for guidance only, and are not to be considered a mandatory
requirement for data collection, analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following immunisation to allow for
comparability of data, and are recommended as an addition to data
collected for the specific study question and setting. The guidelines
are not intended to guide the primary reporting of SGA to a surveil-
lance system or study monitor. Investigators developing a data col-
lection tool based on these data collection guidelines also need to
refer to the criteria in the case definition, which are not repeated in
these guidelines.
Guideline numbers below have been developed to address data
elements for the collection of adverse event information as speci-
fied in general drug safety guidelines by the International Confer-
ence on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use [92], and the form
for reporting of drug adverse events by the Council for Interna-
tional Organizations of Medical Sciences [93]. These data elements
include an identifiable reporter and patient, one or more prior
immunisations, and a detailed description of the adverse event,
in this case, of SGA following immunisation. The additional guide-
lines have been developed as guidance for the collection of addi-
tional information to allow for a more comprehensive
understanding of SGA following immunisation.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting5 and/or
diagnosing the SGA as specified by country-specific data pro-
tection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., immuniser [clinician,nurse],
family member [indicaterelationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws). Full name should be
used if privacy rules permit to avoid a misclassification.
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.
3.1.2.2. Clinical and immunisation history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Past medical history, including hospitalisations, underly-
ing diseases/disorders, pre-immunisation signs and symp-
toms including identification of indicators for, or the
absence of, a history of allergy to vaccines, vaccine compo-
nents or medications; food allergy; allergic rhinitis;
eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunisation includ-
ing prescription and non-prescription medication, as well
5 If the reporting centre is different from the vaccinating centre, appropriate and
timely communication of the adverse event should occur.
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as medication or treatment with long half-life or long term
effect. (e.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunisation history (i.e. previous immunisations and any
adverse event following immunisation (AEFI)), in particular
occurrence of SGA after a previous immunisation.
3.1.3. Details of the immunisation
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of immunisation(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunisations against the same disease).
(13) The anatomical sites (including left or right side) of all
immunisations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Clinical description of signs and symptoms of SGA, and if
there was medical confirmation of the event (i.e. patient
seen by physician).
(18) Date/time of onset,6 first observation7 and diagnosis,8 end of
episode9 and final outcome.10
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testing
 Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
 Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.
(21) Treatment given for SGA.
(22) Outcome9 at last observation.
(23) Objective clinical evidence supporting classification of the
event as ‘‘serious”.11
(24) Exposures other than the immunisation 24 h before and
after immunisation (e.g. food, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The duration of surveillance for SGA should be predefined
based on the relatively narrow window of time for diagnosis
at birth.
(26) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1 to 24.
(29) Investigators of patients with SGA should provide guidance
to reporters to optimise the quality and completeness of
information provided.
(30) Reports of SGA should be collected throughout the study
period regardless of the time elapsed between immunisation
and the adverse event. If this is not feasible due to the study
design, the study periods during which safety data are being
collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on SGA to allow for comparability of data, and
are recommended as an addition to data analysed for the specific
study question and setting.
(31) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
3.2.1. Event classification in 5 categories12
3.2.1.1. Event meets case definition.
Level 1: Criteria as specified in the SGA case definition.
Level 2: Criteria as specified in the SGA case definition
Level 3: Criteria as specified in the SGA case definition
3.2.2. Event does not meet case definition
3.2.2.1. Additional categories for analysis.
(4) Reported SGA with insufficient evidence to meet the case
definition13
(5) Not a case of SGA14
(32) The interval between immunisation and reported SGA could
be defined as the date/time of immunisation to the date/-
time of diagnosis. It should be noted that the diagnosis of
6 The date and/or time of onset is defined as the time post immunisation, when the
first sign or symptom indicative for SGA occurred. This may only be possible to
determine in retrospect.
7 The date and/or time of first observation of the first sign or symptom indicative
for SGA can be used if date/time of onset is not known.
8 The date of diagnosis of an episode is the day post immunisation when the event
met the case definition at any level.
9 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition.
10 E.g. recovery to pre-immunisation health status, spontaneous resolution, thera-
peutic intervention, persistence of the event, sequelae, death.
11 An AEFI is defined as serious by international standards if it meets one or more of
the following criteria: (1) it results in death, (2) is life-threatening, (3) it requires
inpatient hospitalisation or results in prolongation of existing hospitalisation, (4)
results in persistent or significant disability/incapacity, (5) is a congenital anomaly/
birth defect, (6) is a medically important event or reaction.
12 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a
given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case definition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the event should be classified in additional categories four or five.
13 If the evidence available for an event is insufficient because information is
missing, such an event should be categorised as ‘‘Reported SGA with insufficient
evidence to meet the case definition”.
14 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of SGA”.
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SGA is made at birth whereas any damage due to immunisa-
tion or another exposure happened during the pregnancy.
Thus the interval between immunisation date and the date
of diagnosis is less useful than in classical vaccine associa-
tion studies.
3.3. Subjects with small for gestational age by interval to presentation
3.3.1. Interval (diagnosis of SGA made at delivery) number/percent
Immunisation >12 weeks prior to SGA diagnosis.
Immunisation >8 and <12 weeks prior to SGA diagnosis.
Immunisation >4 and <8 weeks prior to SGA diagnosis.
Immunisation <4 weeks prior to SGA diagnosis.
Weekly increments thereafter.
4. Total
(33) The duration of a possible SGA could be analysed as the
interval between the date/time of diagnosis or birth. What-
ever start and ending are used, they should be used consis-
tently within and across study groups.
(34) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(35) The distribution of data (as numerator and denominator
data) could be analysed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.
(36) Data on SGA obtained from subjects receiving a vaccine
should be compared with those obtained from an appropri-
ately selected and documented control group(s) to assess
background rates of hypersensitivity in non-exposed popu-
lations, and should be analysed by study arm and dose
where possible, e.g. in prospective clinical trials.
4.1. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on SGA following immunisation to
allow for comparability of data, and are recommended as an addi-
tion to data presented for the specific study question and setting.
Additionally, it is recommended to refer to existing general guide-
lines for the presentation and publication of randomised controlled
trials, systematic reviews, and meta-analyses of observational
studies in epidemiology (e.g. statements of Consolidated Standards
of Reporting Trials (CONSORT), of Improving the quality of reports
of meta-analyses of randomised controlled trials (QUORUM), and
of meta-analysis Of Observational Studies in Epidemiology
(MOOSE), respectively) [94–96].
(37) All reported events of SGA should be presented according to
the categories listed in guideline 31.
(38) Data on possible SGA events should be presented in accor-
dance with data collection guidelines 1–24 and data analysis
guidelines 31–36.
(39) Terms to describe SGA such as ‘‘low-grade”, ‘‘mild”, ‘‘moder-
ate”, ‘‘high”, ‘‘severe” or ‘‘significant” are highly subjective,
prone to wide interpretation, and should be avoided, unless
clearly defined.
(40) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunisation safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomina-
tor data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(41) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(42) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(43) Any publication of data on SGA should include a detailed
description of the methods used for data collection and anal-
ysis as possible. It is essential to specify:
 The study design;
 The method, frequency and duration of monitoring for
SGA;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The typeof surveillance (e.g. passive or active surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of immunisation was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset5 and/or the date of first obser-
vation6 and/or the date of diagnosis7 was used for analy-
sis; and
 Use of this case definition for SGA, in the abstract or
methods section of a publication.15
Disclaimer
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conclusions in this paper are those of the authors and do not nec-
essarily represent the views of their respective institutions.
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